N2OFF Highlights Co-Founder’s Groundbreaking Research on Mitochondrial Carriers Under Spaceflight Stress Conditions

N2OFF, Inc. (NASDAQ: NITO), a drug discovery company that also invests in solar energy assets through its RTB (Ready to Build) business model, has drawn attention to a newly published peer‑reviewed scientific paper co‑authored by Prof. Ciro Leonardo Pierri, co‑founder of its wholly owned subsidiary MitoCareX Bio Ltd. The study, published in the *Journal of Translational Medicine* on December 30, 2025, explores mitochondrial SLC25A carriers as potential biomarkers and therapeutic targets for dysfunctions triggered by spaceflight conditions such as microgravity and cosmic radiation. The paper, titled “SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight‑induced dysfunction: the ADP/ATP carrier (AAC3) as a structural case study,” uses transcriptomic data from NASA’s Open Science Data Repository to examine changes in the expression of 53 SLC25A genes in bone cells, human stem cells, and mouse brain tissue exposed to spaceflight‑like stressors. Researchers identified significant changes in multiple SLC25A carriers, suggesting their value as indicators of mitochondrial and metabolic dysfunction. A focused analysis on the ADP/ATP carrier AAC3 demonstrates how structural and functional insights might guide new strategies to protect or restore mitochondrial energy balance under stress. Although the study was conducted independently with collaborators at the University of Bari “Aldo Moro” and the University of Pittsburgh, the findings align closely with MitoCareX Bio’s scientific focus. Using its proprietary MITOLINE™ computational platform, MitoCareX Bio aims to model and virtually screen small molecules that target SLC25A mitochondrial carriers — proteins central to cellular energy production and implicated in cancer metabolism, therapy resistance, and rare inherited disorders. The research highlights Prof. Pierri’s expertise in structural biology and mitochondrial carrier modeling, adding foundational scientific support to MitoCareX Bio’s precision oncology pipeline. #MitochondrialResearch #SpaceflightScience #DrugDiscovery #BiotechInnovation #SlimScan #GrowthStocks #CANSLIM